Abstract: Disclosed herein are non-endogenous, constitutively activated forms of the human 5-HT2A and human 5-HT2C receptors and uses of such receptors to screen candidate compounds. Further disclosed herein are candidate compounds identified by the screening method which act at the 5HT2A receptors. Yet further disclosed is a new class of compounds which act at the 5HT2A receptors.
Type:
Grant
Filed:
April 14, 1999
Date of Patent:
April 1, 2003
Assignee:
Arena Pharmaceuticals, Inc.
Inventors:
Dominic P. Behan, Derek T. Chalmers, Chen W. Liaw, Joseph F. Russo, William J. Thomsen
Abstract: Disclosed herein are quinoline derivatives having dual mechanistic properties, referred to in this patent document as “acetylcholine enhancers”, i.e., compounds which evidence acetylcholinesterase (AChE) inhibition activity, and 5-HT3 receptor antagonist activity. A particularly preferred compound is 2-[2-(1-benzylpiperizin-4-yl) ethyl]-2,3-dihydro-9-methoxy-1H-pyrrolo [3,4-b] quinolin-1-one hemifumarate, referred to herein as Compound A (“Cm.A”).
Abstract: Drink bottles are provided having improve sanitation. In accordance with the preferred feature of the invention, a barrier is disposed around the spout of a squeezable drink bottle so as to inhibit contact between the end of the spout from which liquid is expressed and the lips of a person receiving liquid from a bottle. Elimination of reflux and improved sanitation results.